1 Day
المصدر:
New York Post
New York Post
جاهز للتشغيل
جاهز للتشغيل
A recent case highlights concerns over AlloClae, a non-surgical breast enhancement product made from donor-derived fat, which debuted in the US in 2024. Users have reported complications such as lumps, cysts, and pain, with some experiencing lasting tissue damage. The product is under legal dispute in New York, where regulators allege improper distribution, while medical professionals warn about risks like fat necrosis, though official safety data remains limited.
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading